Page 1

Interim report third quarter 2021 Capital injection initiates a new phase of accelerated expansion Third quarter ( July - September 2021 ) ● ● Revenues amounted to SEK 45.2 ( 34.1 ) million , an increase of 32 % . Adjusted for currency effects revenues increased by 36 % . EBITDA amounted to SEK 1.2 ( -3.1 ) million with an EBITDA margin of 3 % ( -9 % ) . Operating profit amounted to SEK -10.7 ( -14.3 ) million . Net loss for the period amounted to SEK -10.8 ( -16.1 ) million . Earnings per share amounted to SEK -0.31 ( -0.48 ) . Cash flow from operating activities amounted to SEK 14.3 ( -3.3 ) million , corresponding to SEK 0.41 ( -0.10 ) per share . Key events during the third quarter The Board of Bactiguard appointed Anders Göransson as new CEO from 1 October . Through a directed new share issue to AMF , Bactiguard received approximately SEK 228 million in new capital before transaction costs . Carl Johan Fredin was recruited to the role of Chief Licensing Officer and took up the position in October . Aniocyn , the wound care product for animals , has been launched and is now available in Sweden , Norway and Finland . Bactiguard's contract for wound care products with the public sector in Malaysia was extended by another year with increased volumes . Key figures Revenues² , SEKm EBITDA³ , SEKM EBITDA margin³ , % Net profit / loss for the period² , SEKm Adjusted net profit / loss for the period¹ , 3 , SEKM Earnings per share² , SEK Adjusted earnings per share¹ , 3 , SEK Operating cash flow² , SEKm Operating cash flow per share³ , SEK Equity ratio³ , % Net debt³ , SEKm Jul - Sep 2021 45,2 1,2 3 % -10,8 -10,8 -0,31 -0,31 14,3 0,41 65 % 13,2 Nine - month period ( January - September 2021 ) Revenues amounted to SEK 133.0 ( 130.5 ) million , an increase of 2 % . Adjusted for currency effects revenues increased by 10 % . ● 2 Defined according to IFRS . 3 Alternative performance measure . For definition and reconciliation , see pages 19-20 ● BACTIGUARD HOLDING AB ( publ ) Corporate registration number 556822-1187 Jul - Sep 2020 34,1 -3,1 -9 % -16,1 -16,1 -0,48 -0,48 -3,3 -0,10 56 % 250,1 Bactiguard Operating profit amounted to SEK -30.4 ( -11.2 ) million . Net loss for the period amounted to SEK -33.4 ( -27.6 ) million . Earnings per share amounted to SEK -0.95 ( -0.82 ) . Cash flow from operating activities amounted to SEK 18.9 ( -3.2 ) million , corresponding to SEK 0.54 ( -0.10 ) per share . Key events after the end of the quarter EBITDA amounted to SEK 4.9 ( 21.8 ) million , with an EBITDA margin of 4 % ( 17 % ) . New clinical study shows 53 % reduction in ventilator - associated pneumonia with Bactiguard's endotracheal tube . Covid - 19 effects The global roll - out of vaccines and fewer new covid cases have gradually had a positive effect on the return to a more normal situation for healthcare in most regions . During the third quarter , we saw a continued stabilization of license revenues from BD . At the same time , a global healthcare backlog has been built up and must be managed . In this perspective , we see a great need for infection prevention , which is positive for both the licensing and BIP business . However , near term developments remain difficult to assess , as new virus outbreaks cannot be ruled out . Jan - Sep Jan - Sep Full Year 2021 2020 2020 133,0 4,9 4 % -33,4 -33,4 -0,95 -0,95 18,9 0,54 65 % 13,2 130,5 21,8 17 % -27,6 -16,7 -0,82 -0,50 -3,2 -0,10 56 % 250,1 186,0 26,7 14 % -38,4 -27,5 -1,14 -0,82 0,7 0,02 55 % 254,1 RTM 2021 188,6 9,8 5 % 1 The part of the purchase price for the acquisition of Vigilenz that consisted of shares is considered , for accounting purposes , as a financial instrument and the forward effect is thus reported as a financial item in the income statement and has affected net profit / loss for the second quarter 2020 with SEK 1,9 million and full year 2020 with SEK -10.9 million . The adjustment is only affecting accounting and has no effect on cash flow . -44,2 -44,2 -1,26 -1,26 22,8 0,65 65 % 13,2 1